<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588991</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00259</org_study_id>
    <secondary_id>NCI-2009-00259</secondary_id>
    <secondary_id>CDR0000579626</secondary_id>
    <secondary_id>J0783</secondary_id>
    <secondary_id>7968</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>UM1CA186691</secondary_id>
    <nct_id>NCT00588991</nct_id>
  </id_info>
  <brief_title>Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders</brief_title>
  <official_title>A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of veliparib when given&#xD;
      together with topotecan hydrochloride with or without carboplatin in treating patients with&#xD;
      relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive&#xD;
      myeloproliferative disorders. Veliparib may stop the growth of cancer cells by blocking some&#xD;
      of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan&#xD;
      hydrochloride and carboplatin, work in different ways to stop the growth of cancer cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving veliparib together with&#xD;
      topotecan hydrochloride and carboplatin may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility, tolerability, and toxicities of ABT-888 (veliparib) when&#xD;
      administered alone and in combination with topotecan hydrochloride with or without&#xD;
      carboplatin in patients with relapsed or refractory acute leukemia, high-risk myelodysplasia,&#xD;
      or aggressive myeloproliferative disorders.&#xD;
&#xD;
      II. To determine the maximum tolerated dose of ABT-888 when administered with topotecan&#xD;
      hydrochloride and carboplatin in these patients.&#xD;
&#xD;
      III. To determine if ABT-888 when administered with topotecan hydrochloride and carboplatin&#xD;
      can induce clinical responses in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the pharmacokinetics of ABT-888 when administered alone and in combination&#xD;
      with topotecan hydrochloride with or without carboplatin in these patients.&#xD;
&#xD;
      II. To obtain pharmacodynamic data regarding the ability of ABT-888 to inhibit poly&#xD;
      (ADP-ribose) levels in leukemic blasts.&#xD;
&#xD;
      III. To obtain descriptive data regarding the mutational status and/or methylation status of&#xD;
      key genes in selected DNA repair pathways (Fanconi complementation groups A-F, Blooms, and&#xD;
      ataxia-telangiectasia) in leukemic blasts.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of veliparib.&#xD;
&#xD;
      Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan&#xD;
      hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7.&#xD;
      Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2007</start_date>
  <primary_completion_date type="Actual">February 1, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of veliparib, determined as the highest dose level where 0/3 or 1/6 experience DLT, measured according to NCI-CTCAE 4.0</measure>
    <time_frame>Up to 63 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response (CR, CRi, PR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of veliparib</measure>
    <time_frame>Day 1 at pre-treatment, .25, .5, 1, 2, 4, 6, and 8 hours after veliparib and day 4 at pre-veliparib, .25, .5, 1, 2, 4, 6, and 8 hours after the first dose of veliparib</time_frame>
    <description>Relevant individual PK parameters will be estimated using non-compartmental PK methods. PK parameters will be compared when administered alone or in combination by a paired student's t-test. Comparison of PK parameters among dose levels will be performed using non-parametric statistical methods for K-independent samples. Associations between exposure parameters (Cmax and AUC) and pharmacodynamic endpoints (cellular PAR levels, mutation and/or altered expression of selected DNA repair genes) will be assessed using the appropriate non-parametric statistical tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Adult Acute Megakaryoblastic Leukemia</condition>
  <condition>Adult Acute Monoblastic Leukemia</condition>
  <condition>Adult Acute Monocytic Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With Maturation</condition>
  <condition>Adult Acute Myeloid Leukemia With Minimal Differentiation</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL</condition>
  <condition>Adult Acute Myeloid Leukemia Without Maturation</condition>
  <condition>Adult Acute Myelomonocytic Leukemia</condition>
  <condition>Adult Erythroleukemia</condition>
  <condition>Adult Pure Erythroid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (veliparib, topotecan hydrochloride, carboplatin)</arm_group_label>
    <other_name>ABT-888</other_name>
    <other_name>PARP-1 inhibitor ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of 1 of aggressive MPD or AML out of MPD&#xD;
&#xD;
          -  Aggressive phase high-risk myeloproliferative disorders (i.e., polycythemia vera,&#xD;
             essential thrombocythemia, or Ph-negative chronic myelogenous leukemia) meeting ≥ 1 of&#xD;
             the following criteria:&#xD;
&#xD;
               -  Marrow blasts &gt; 5%&#xD;
&#xD;
               -  Peripheral blood blasts plus progranulocytes &gt; 10%&#xD;
&#xD;
               -  New onset or increasing myelofibrosis OR;&#xD;
&#xD;
          -  New onset or &gt; 25% increase in hepatomegaly or splenomegaly&#xD;
&#xD;
          -  New onset constitutional symptoms (i.e., fever, weight loss, splenic pain, or bone&#xD;
             pain)&#xD;
&#xD;
          -  Patients who failed primary induction therapy or relapsed after achieving complete&#xD;
             remission are eligible&#xD;
&#xD;
          -  No active CNS leukemia; patients with a history of CNS disease must be stable for &gt; 3&#xD;
             months after treatment and off steroid treatment prior to study enrollment&#xD;
&#xD;
          -  Chronic myelomonocytic leukemia meeting either of the following criteria:&#xD;
&#xD;
               -  5-19% bone marrow blasts (aggressive)&#xD;
&#xD;
               -  At least 20% marrow blasts (transformation)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  No hyperleukocytosis with &gt;= 50,000 blasts/uL&#xD;
&#xD;
          -  AST, ALT, and alkaline phosphatase =&lt; 5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  LVEF &gt;= 45% by MUGA or ECHO&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No active disseminated intravascular coagulation&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  Patients with infection that is under active treatment and controlled with antibiotics&#xD;
             are eligible&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No mental deficits and/or psychiatric history that would preclude giving informed&#xD;
             consent or following protocol&#xD;
&#xD;
          -  No prior or current seizure disorder or a history of seizure&#xD;
&#xD;
          -  No more than 3 prior cytotoxic regimens&#xD;
&#xD;
          -  At least 3 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          -  No active graft-versus-host disease&#xD;
&#xD;
          -  At least 1 week since prior biologic therapies, including hematopoietic growth factors&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic&#xD;
             trioxide, interferon, or other noncytotoxic agents for blast count control&#xD;
&#xD;
          -  No prior ABT-888&#xD;
&#xD;
          -  No other concurrent chemotherapy, radiotherapy, or immunotherapy&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith W Pratz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

